Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine
The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2017/02/01, Vol.56(3), pp.335-339 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 339 |
|---|---|
| container_issue | 3 |
| container_start_page | 335 |
| container_title | Internal Medicine |
| container_volume | 56 |
| creator | Iwaku, Kenji Otuka, Fumiko Taniyama, Matsuo |
| description | The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with type 1 diabetes (glutamic acid decarboxylase (GAD)-Ab: 5.6 U/mL, IA-2 Ab: 5.9 U/mL, fasting C-peptide: 0.12 ng/mL) and was put on intensive insulin therapy. At four months after the onset of 1A diabetes, he experienced a honeymoon phase that was sustained until the 40th month of treatment. We hypothesize that the administration of olanzapine to a patient with pre-type 1A diabetes induced marked hyperglycemia and accelerated the onset of type 1A diabetes. |
| doi_str_mv | 10.2169/internalmedicine.56.7010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5348459</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2246916290</sourcerecordid><originalsourceid>FETCH-LOGICAL-c642t-f1253855c524821ecc003ad9e3eba195195a6e947bece82d2f5354fd2a3d531d3</originalsourceid><addsrcrecordid>eNqNkV2LEzEUhoMobl39CxLwxpupk48zk9wIZesXLBZkvQ5p5kybMs3UJLOw_npTWosuXgjhBJLnvHlPXkIoq-ecNfqdDxljsMMeO-98wDk087Zm9RMyY0LqquUCnpJZrZmqeClX5EVKu7oWqtX8ObniioHkrZ6Rbws3ZaxWIWGmdw8HpIwuvV1jxkTz1ma6xHscxgN2dDlFHzblFOmi2_vgU442-zHQsaerwYaf9lDMvCTPejskfHXer8n3jx_ubj5Xt6tPX24Wt5VrJM9VzzgIBeCAS8UZOlf82U6jwLVlGsqyDWrZrtGh4h3vQYDsO25FB4J14pq8P-kepnX5CIeh2BnMIfq9jQ9mtN78fRP81mzGewNCKgm6CLw9C8Txx4Qpm71PDocyCY5TMkwp1jY1a-E_0AYAZAttQd88QnfjdAwrGc5lo1nDdV0odaJcHFOK2F98s9ocMzaPMzbQmGPGpfX1n3NfGn-HWoCvJ2CXst3gBbAxezfgP5XFsZxfuIBua6PBIH4BlKzE-A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2246916290</pqid></control><display><type>article</type><title>Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine</title><source>J-STAGE Free</source><source>MEDLINE</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Iwaku, Kenji ; Otuka, Fumiko ; Taniyama, Matsuo</creator><creatorcontrib>Iwaku, Kenji ; Otuka, Fumiko ; Taniyama, Matsuo</creatorcontrib><description>The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with type 1 diabetes (glutamic acid decarboxylase (GAD)-Ab: 5.6 U/mL, IA-2 Ab: 5.9 U/mL, fasting C-peptide: 0.12 ng/mL) and was put on intensive insulin therapy. At four months after the onset of 1A diabetes, he experienced a honeymoon phase that was sustained until the 40th month of treatment. We hypothesize that the administration of olanzapine to a patient with pre-type 1A diabetes induced marked hyperglycemia and accelerated the onset of type 1A diabetes.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.56.7010</identifier><identifier>PMID: 28154279</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Adult ; Antipsychotic Agents - adverse effects ; Benzodiazepines - administration & dosage ; Benzodiazepines - adverse effects ; Beverages ; Blood Glucose ; Case Report ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (insulin dependent) ; Diabetes Mellitus, Type 1 - diagnosis ; Diabetes Mellitus, Type 1 - physiopathology ; Diabetic Ketoacidosis - chemically induced ; Diabetic Ketoacidosis - drug therapy ; Glucose ; Glutamate decarboxylase ; Glutamic acid ; Humans ; Hyperglycemia ; Hyperglycemia - chemically induced ; Hyperglycemia - drug therapy ; Insulin ; Insulin - therapeutic use ; Internal medicine ; Ketoacidosis ; Male ; Mental disorders ; multi-acting-receptor-targeted anti-psychotics ; Olanzapine ; Polyuria ; Prediabetic State - complications ; Prediabetic State - diagnosis ; Schizophrenia ; Schizophrenia - drug therapy ; Thirst ; type 1 diabetes mellitus</subject><ispartof>Internal Medicine, 2017/02/01, Vol.56(3), pp.335-339</ispartof><rights>2017 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c642t-f1253855c524821ecc003ad9e3eba195195a6e947bece82d2f5354fd2a3d531d3</citedby><cites>FETCH-LOGICAL-c642t-f1253855c524821ecc003ad9e3eba195195a6e947bece82d2f5354fd2a3d531d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348459/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348459/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1881,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28154279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iwaku, Kenji</creatorcontrib><creatorcontrib>Otuka, Fumiko</creatorcontrib><creatorcontrib>Taniyama, Matsuo</creatorcontrib><title>Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with type 1 diabetes (glutamic acid decarboxylase (GAD)-Ab: 5.6 U/mL, IA-2 Ab: 5.9 U/mL, fasting C-peptide: 0.12 ng/mL) and was put on intensive insulin therapy. At four months after the onset of 1A diabetes, he experienced a honeymoon phase that was sustained until the 40th month of treatment. We hypothesize that the administration of olanzapine to a patient with pre-type 1A diabetes induced marked hyperglycemia and accelerated the onset of type 1A diabetes.</description><subject>Adult</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Benzodiazepines - administration & dosage</subject><subject>Benzodiazepines - adverse effects</subject><subject>Beverages</subject><subject>Blood Glucose</subject><subject>Case Report</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Diabetes Mellitus, Type 1 - diagnosis</subject><subject>Diabetes Mellitus, Type 1 - physiopathology</subject><subject>Diabetic Ketoacidosis - chemically induced</subject><subject>Diabetic Ketoacidosis - drug therapy</subject><subject>Glucose</subject><subject>Glutamate decarboxylase</subject><subject>Glutamic acid</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hyperglycemia - chemically induced</subject><subject>Hyperglycemia - drug therapy</subject><subject>Insulin</subject><subject>Insulin - therapeutic use</subject><subject>Internal medicine</subject><subject>Ketoacidosis</subject><subject>Male</subject><subject>Mental disorders</subject><subject>multi-acting-receptor-targeted anti-psychotics</subject><subject>Olanzapine</subject><subject>Polyuria</subject><subject>Prediabetic State - complications</subject><subject>Prediabetic State - diagnosis</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Thirst</subject><subject>type 1 diabetes mellitus</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV2LEzEUhoMobl39CxLwxpupk48zk9wIZesXLBZkvQ5p5kybMs3UJLOw_npTWosuXgjhBJLnvHlPXkIoq-ecNfqdDxljsMMeO-98wDk087Zm9RMyY0LqquUCnpJZrZmqeClX5EVKu7oWqtX8ObniioHkrZ6Rbws3ZaxWIWGmdw8HpIwuvV1jxkTz1ma6xHscxgN2dDlFHzblFOmi2_vgU442-zHQsaerwYaf9lDMvCTPejskfHXer8n3jx_ubj5Xt6tPX24Wt5VrJM9VzzgIBeCAS8UZOlf82U6jwLVlGsqyDWrZrtGh4h3vQYDsO25FB4J14pq8P-kepnX5CIeh2BnMIfq9jQ9mtN78fRP81mzGewNCKgm6CLw9C8Txx4Qpm71PDocyCY5TMkwp1jY1a-E_0AYAZAttQd88QnfjdAwrGc5lo1nDdV0odaJcHFOK2F98s9ocMzaPMzbQmGPGpfX1n3NfGn-HWoCvJ2CXst3gBbAxezfgP5XFsZxfuIBua6PBIH4BlKzE-A</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Iwaku, Kenji</creator><creator>Otuka, Fumiko</creator><creator>Taniyama, Matsuo</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine</title><author>Iwaku, Kenji ; Otuka, Fumiko ; Taniyama, Matsuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c642t-f1253855c524821ecc003ad9e3eba195195a6e947bece82d2f5354fd2a3d531d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Benzodiazepines - administration & dosage</topic><topic>Benzodiazepines - adverse effects</topic><topic>Beverages</topic><topic>Blood Glucose</topic><topic>Case Report</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Diabetes Mellitus, Type 1 - diagnosis</topic><topic>Diabetes Mellitus, Type 1 - physiopathology</topic><topic>Diabetic Ketoacidosis - chemically induced</topic><topic>Diabetic Ketoacidosis - drug therapy</topic><topic>Glucose</topic><topic>Glutamate decarboxylase</topic><topic>Glutamic acid</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hyperglycemia - chemically induced</topic><topic>Hyperglycemia - drug therapy</topic><topic>Insulin</topic><topic>Insulin - therapeutic use</topic><topic>Internal medicine</topic><topic>Ketoacidosis</topic><topic>Male</topic><topic>Mental disorders</topic><topic>multi-acting-receptor-targeted anti-psychotics</topic><topic>Olanzapine</topic><topic>Polyuria</topic><topic>Prediabetic State - complications</topic><topic>Prediabetic State - diagnosis</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Thirst</topic><topic>type 1 diabetes mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iwaku, Kenji</creatorcontrib><creatorcontrib>Otuka, Fumiko</creatorcontrib><creatorcontrib>Taniyama, Matsuo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iwaku, Kenji</au><au>Otuka, Fumiko</au><au>Taniyama, Matsuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>56</volume><issue>3</issue><spage>335</spage><epage>339</epage><pages>335-339</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with type 1 diabetes (glutamic acid decarboxylase (GAD)-Ab: 5.6 U/mL, IA-2 Ab: 5.9 U/mL, fasting C-peptide: 0.12 ng/mL) and was put on intensive insulin therapy. At four months after the onset of 1A diabetes, he experienced a honeymoon phase that was sustained until the 40th month of treatment. We hypothesize that the administration of olanzapine to a patient with pre-type 1A diabetes induced marked hyperglycemia and accelerated the onset of type 1A diabetes.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>28154279</pmid><doi>10.2169/internalmedicine.56.7010</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2017/02/01, Vol.56(3), pp.335-339 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5348459 |
| source | J-STAGE Free; MEDLINE; PubMed Central Open Access; PubMed Central |
| subjects | Adult Antipsychotic Agents - adverse effects Benzodiazepines - administration & dosage Benzodiazepines - adverse effects Beverages Blood Glucose Case Report Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Diabetes Mellitus, Type 1 - diagnosis Diabetes Mellitus, Type 1 - physiopathology Diabetic Ketoacidosis - chemically induced Diabetic Ketoacidosis - drug therapy Glucose Glutamate decarboxylase Glutamic acid Humans Hyperglycemia Hyperglycemia - chemically induced Hyperglycemia - drug therapy Insulin Insulin - therapeutic use Internal medicine Ketoacidosis Male Mental disorders multi-acting-receptor-targeted anti-psychotics Olanzapine Polyuria Prediabetic State - complications Prediabetic State - diagnosis Schizophrenia Schizophrenia - drug therapy Thirst type 1 diabetes mellitus |
| title | Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T12%3A45%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute-Onset%20Type%201%20Diabetes%20that%20Developed%20During%20the%20Administration%20of%20Olanzapine&rft.jtitle=Internal%20Medicine&rft.au=Iwaku,%20Kenji&rft.date=2017-01-01&rft.volume=56&rft.issue=3&rft.spage=335&rft.epage=339&rft.pages=335-339&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.56.7010&rft_dat=%3Cproquest_pubme%3E2246916290%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2246916290&rft_id=info:pmid/28154279&rfr_iscdi=true |